
Gabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide Combination
The Gabrail Cancer Center Undertakes Investigator-Initiated Study Evaluating the T-Cell Engager Elranatamab in Combination with Starton Therapeutics’ Controlled Low-Dose Lenalidomide The Gabrail Cancer and Research Center, a PhaseWell Research site, announced that Nashat Gabrail, M.D., has received notification from the…













